Evidence map›Paper›PMID 42596577›Full record

ArticleEpilepsia2026

Could calcitonin gene-related peptide inhibitors prevent status epilepticus?

Michael Nsaka, Noor Baban, Sepideh Allahdadian, Armin Scheffler, Diana Lindner, Dagny Holle, Alain Lekoubou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael NsakaDepartment of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-7090-0077
Noor BabanDrexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Sepideh AllahdadianDepartment of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Armin SchefflerDepartment of Neurology and Centre for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0009-0002-2266-7431
Diana LindnerDepartment of Neurology and Centre for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Dagny HolleDepartment of Neurology and Centre for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0003-4872-0384
Alain LekoubouDepartment of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-2416-5622

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcitonin gene-related peptide (CGRP) inhibitors modulate pain and neuroinflammation, a recognized contributor to epileptogenesis and status epilepticus (SE). We examined the association between CGRP inhibitor use and SE hospitalization in epilepsy patients with comorbid migraine. Using TriNetX (130 healthcare organizations), we identified patients with epilepsy from May 2018 through May 2026, and propensity-matched cohorts for age, sex, race, anti-seizure medications (ASMs), migraine diagnosis, migraine treatments, and cognitive impairment. The primary outcome was SE occurrence. Following matching, 17 738 patients were on CGRP inhibitors and 18 594 were not. SE occurred in 427 (2.41%) and 860 (4.63%) patients, respectively. Mean age (±SD) was 48.4 ± 14.9 vs 48.9 ± 17.0 years. Risk difference was -2.2% (95% confidence interval [CI]: -2.6% to -1.8%, p < .001), risk ratio 0.52 (95% CI: 0.46-0.58), and odds ratio 0.51 (95% CI: 0.45-0.57). SE-related hospital visits were significantly fewer in the CGRP inhibitor group (t = -6.60, p < .001). CGRP inhibitor use was associated with reduced SE occurrence and hospitalization, supporting further investigation in patients with comorbid migraine and epilepsy.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersStatus EpilepticusAdultAnticonvulsantsEpilepsyFemaleHospitalizationHumansMaleMiddle AgedAnticonvulsantsCalcitonin Gene-Related PeptideCGRP inhibitorsepilepsymigraineneuroinflammationstatus epilepticus

Identifiers

PMID42596577
PMCPMC13675781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.